Emerging Techniques in Cancer Therapy: Precision Targeting for Improved Outcomes

Abstract

The continuous evolution of cancer therapy has driven the exploration of novel strategies to improve treatment specificity and efficacy while minimizing adverse effects. This article examines two innovative approaches that offer new directions in targeting cancer cells. The first approach focuses on developing antibodies that specifically bind to peptide/major histocompatibility complex (MHC) complexes, enhancing the precision and effectiveness of immunotherapy. The second approach introduces quinazoline compounds that target and inhibit critical tyrosine kinases in cancer progression. Together, these advancements represent promising strides in the quest to develop more effective and precise cancer therapies, offering promising new avenues for treating resistant and aggressive forms of cancer. ImportantCompound Classes. Titles. Quinazoline Compound for Inducing Degradation of G12D-Mutation KRAS Protein; Compositions and Methods Comprising Antibodies that Bind Covalent Peptide Conjugates. Patent Publication Numbers. EP 4293024 A1 (URL: https://patents.google.com/patent/EP4293024A1/en?oq= EP+4293024+A1)WO 2023/250391 A2 (URL: https://patents.google.com/ p a t e n t / W O 2 0 2 3 2 5 0 3 9 1 A 2 / e n ? o q = WO+2023%2f250391+A2).